BioSpace News Archive

Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle therapeutics as a new class of medicines, announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately.

Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present virtually on January 13, 2022 at 9 a.m. ET, at the 40th J.P. Morgan Healthcare Conference.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 7:30 a.m. ET.

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced that its management will present at the H.C. Wainwright Bioconnect Virtual Conference.

Selecta Biosciences, Inc. announced that Company’s Management will provide a corporate update at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022.

Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference.

Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that it entered into a definitive agreement on December 31, 2021 to acquire substantially all of the assets related to AuraGen Aesthetic, LLC’s novel fat grafting technology, the AuraGen 1-2-3™ with AuraClens™.

Daxor Corporation, the global leader in blood volume measurement technology, announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor’s BVA-100 technology in hospitalized COVID-19 patients.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD).

Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, provided a corporate update and announced its strategic priorities and anticipated milestones.